Neuren Pharmaceuticals Limited
(ASX:NEU) has entered into a trading halt pending an announcement about its lead product’s clinical trial.
The company which develops brain injury and disorder treatment requested the halt after the market closed on Friday.
The halt is expected to remain until Wednesday 22 March or until Neuren announces a statement about Phase 2 of its clinical trial in Rett syndrome, and how its lead product trofinetide is used.
The company says its already conducted double-blind placebo-controlled Phase 2 trials in both Rett syndrome and Fragile X syndrome and found benefit from their product, trofinetide.
Shares in Neuren Pharmaceuticals Limited
(ASX:NEU) last traded flat on Friday at 8 cents.
